Yazar "Ciltas, Aydin" seçeneğine göre listele
Listeleniyor 1 - 5 / 5
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (MCRPC) after docetaxel chemotherapy: Multicentric experience of Anatolian Society of Medical Oncology(Lippincott Williams & Wilkins, 2014) Demirci, Umut; Oflazoglu, Utku; Kodaz, Hilmi; Ciltas, Aydin; Kefeli, Umut; Akyol, Murat; Ozturk, Banu[Abstract Not Available]Öğe Association of obesity with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry.(Amer Soc Clinical Oncology, 2015) Coskun, Ugur; Altundag, Kadri; Aliustaoglu, Mehmet; Uncu, Dogan; Ozkan, Metin; Cicin, Irfan; Ciltas, Aydin[Abstract Not Available]Öğe Effect of body mass index in gastric cancer patients: Analysis of Turkish national gastric cancer registry(Amer Soc Clinical Oncology, 2015) Ciltas, Aydin; Karaca, Mustafa; Uncu, Dogan; Ozkan, Metin; Aliustaoglu, Mehmet; Tekin, Salim Basol; Cicin, Irfan[Abstract Not Available]Öğe Efficacy and safety of raltitrexed combinations with uracil-tegafur or Mitomycin C as salvage treatment in advanced colorectal cancer patients.(Amer Soc Clinical Oncology, 2014) Ozkan, Metin; Bozkurt, Oktay; Karaca, Halit; Ozaslan, Ersin; Daloglu, Osman Onur; Ciltas, Aydin; Kaplan, Mehmet Ali[Abstract Not Available]Öğe Efficacy and Safety of Raltitrexed Combinations with Uracil-Tegafur or Mitomycin C as Salvage Treatment in Advanced Colorectal Cancer Patients: A Multicenter Study of Anatolian Society of Medical Oncology (ASMO)(Asian Pacific Organization Cancer Prevention, 2014) Bozkurt, Oktay; Karaca, Halit; Ciltas, Aydin; Kaplan, M. Ali; Benekli, Mustafa; Sevinc, Alper; Demirci, UmutBackground: There is no standard treatment for patients with colorectal cancer (CRC) progressing after irinotecan and oxaliplatin treatment. Here we aimed to retrospectively evaluate the efficacy and tolerability of raltitrexed in combination with oral 5-fluoropyrimidine (uracil tegafur-UFT) or mitomycin C as salvage therapy in mCRC patients. Materials and Methods: A total of 62 patients who had received raltitrexed combined with UFT or mitomycin C were identified between December 2008 and June 2013. They were given raltitrexed 2.6 mg/m(2) (max 5 mg) i.v. on day 1 in combination with either oral UFT 500 mg/day on days 1-14 every 3 weeks (group A) or mitomycin C 6 mg/m(2) i.v. on day every 3 weeks (group B). Results: Forty-two patients (67.7%) were in group A and 20 (32.2%) in group B. In 15 patients (24%) grade 3/4 toxicity was observed, resulting in dose reduction, and in 13 patients (20.9%) dose delay was necessary. The median progression free survival (PFS) was 3 months (95% CI 2.65-3.34) and median overall survival (OS) was 6 months (95% CI 2.09-9.90) in the whole group. Median PFS was 3 months (95% CI 2.60-3.39) in group A vs 3 months (95% CI 1.64-4.35) in group B (p=0.90). Median OS was 6 months (95% CI 2.47-9.53) in group A vs 12 months (95% CI 2.83-21.1) in group B (p=0.46). Conclusions: The combination of raltitrexed with UFT or mitomycin C seem to be a salvage therapy option due to safety profile and moderate clinical activity in heavily-pretreated mCRC patients.
